

Multicentre Cancer Chemotherapy Group Randomised Trial of Adjuvant Chemotherapy for 'Early' Breast Cancer

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 18/01/2016	Condition category Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
B27

Study information

Scientific Title
Multicentre Cancer Chemotherapy Group Randomised Trial of Adjuvant Chemotherapy for 'Early' Breast Cancer

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

Following initial local therapy, surgery with or without radiotherapy, patients are randomised to one of 2 treatment arms:

1. Arm A: Tamoxifen 10 mg twice daily for 12 months.
2. Arm B: A total of eight cycles of multidrug chemotherapy. Cyclophosphamide, vincristine and 5-fluorouracil to be given on day 1 and cyclophosphamide, vincristine and methotrexate on day 8 of each 3 week cycle.
3. Arm C: Multidrug chemotherapy with vincristine, methotrexate, chlorambucil and 5-fluorouracil repeated every 3 weeks for 8 cycles.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tamoxifen, cyclophosphamide, vincristine, 5-fluorouracil, methotrexate, chlorambucil

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/12/2005

Eligibility

Key inclusion criteria

1. Aged <70 years
2. Operable primary breast cancer with tumour <5 cm in greatest diameter
3. Histologically proven axillary node involvement
4. Adequate renal and liver function
5. No prior history of other malignant disease
6. No previous chemotherapy

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2000

Date of final enrolment

31/12/2005

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Action Cancer Belfast (UK)

ROR

<https://ror.org/02mf6dg38>

Funder(s)

Funder type

Research organisation

Funder Name

Action Cancer Belfast (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes